158 related articles for article (PubMed ID: 36738874)
21. Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer.
Ritter R; Hennenlotter J; Kühs U; Hofmann U; Aufderklamm S; Blutbacher P; Deja A; Hohneder A; Gerber V; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
Urol Oncol; 2014 Apr; 32(3):337-44. PubMed ID: 24332643
[TBL] [Abstract][Full Text] [Related]
22. Next-generation Proteomics-Based Discovery, Verification, and Validation of Urine Biomarkers for Bladder Cancer Diagnosis.
Suh J; Han D; Ku JH; Kim HH; Kwak C; Jeong CW
Cancer Res Treat; 2022 Jul; 54(3):882-893. PubMed ID: 34645132
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of tumor location and superficial urothelial bladder carcinoma history in patients with ureteral urothelial carcinoma treated with radical nephroureterectomy.
Liu JY; Zhang Q; Ye YL; Li J; Chen W; Li YH; Zhang ZL; Yao K; Jiang LJ; Han H; Liu ZW; Qin ZK; Zhou FJ
Int Urol Nephrol; 2013 Apr; 45(2):395-404. PubMed ID: 23408324
[TBL] [Abstract][Full Text] [Related]
24. An early analysis of the cost-effectiveness of a diagnostic classifier for risk stratification of haematuria patients (DCRSHP) compared to flexible cystoscopy in the diagnosis of bladder cancer.
Sutton AJ; Lamont JV; Evans RM; Williamson K; O'Rourke D; Duggan B; Sagoo GS; Reid CN; Ruddock MW
PLoS One; 2018; 13(8):e0202796. PubMed ID: 30138462
[TBL] [Abstract][Full Text] [Related]
25. Constructing and validating nomograms to predict risk and prognostic factors of distant metastasis in urothelial bladder cancer patients: a population-based retrospective study.
Chen D; Luo Z; Ye C; Luo Q; Fan W; Chen C; Liu G
BMC Urol; 2022 Dec; 22(1):212. PubMed ID: 36575440
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and Prognostic Performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) Assay for Detecting Primary and Recurrent Urinary Bladder Cancer.
Critselis E; Rava M; Marquez M; Lygirou V; Chatzicharalambous D; Liapi P; Lichtinghagen R; Brand K; Cecchini L; Vlahou A; Malats N; Zoidakis J
Proteomics Clin Appl; 2019 Mar; 13(2):e1800148. PubMed ID: 30632279
[TBL] [Abstract][Full Text] [Related]
27. The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer.
Zhang H; Fan Y; Xia L; Gao C; Tong X; Wang H; Sun L; Ji T; Jin M; Gu B; Fan B
Tumour Biol; 2017 Mar; 39(3):1010428317691183. PubMed ID: 28345451
[TBL] [Abstract][Full Text] [Related]
28. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer.
Mbeutcha A; Lucca I; Mathieu R; Lotan Y; Shariat SF
Urol Clin North Am; 2016 Feb; 43(1):47-62. PubMed ID: 26614028
[TBL] [Abstract][Full Text] [Related]
29. UCHL1-PKM2 axis dysregulation is associated with promoted proliferation and invasiveness of urothelial bladder cancer cells.
Zheng Y; Shi D; Chen L; Yang Y; Yao M
Aging (Albany NY); 2023 Oct; 15(19):10593-10606. PubMed ID: 37815895
[TBL] [Abstract][Full Text] [Related]
30. BLCA-4 and UBC combined detection for early diagnosis of bladder cancer.
Cui L; Sun MM; Zhao ZH; Yang JP; Zheng YP; He LL; Chen KS; Fan QX
J Biol Regul Homeost Agents; 2016; 30(2):485-90. PubMed ID: 27358136
[TBL] [Abstract][Full Text] [Related]
31. Proteome-based diagnostics and prognosis of bladder transitional cell carcinoma.
Wu TF; Ku WL; Tsay YG
Expert Rev Proteomics; 2007 Oct; 4(5):639-47. PubMed ID: 17941819
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic inactivation of DNA repair genes as promising prognostic and predictive biomarkers in urothelial bladder carcinoma patients.
Mohanad M; Yousef HF; Bahnassy AA
Mol Genet Genomics; 2022 Nov; 297(6):1671-1687. PubMed ID: 36076047
[TBL] [Abstract][Full Text] [Related]
33. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory biomarkers and bladder cancer prognosis: a systematic review.
Masson-Lecomte A; Rava M; Real FX; Hartmann A; Allory Y; Malats N
Eur Urol; 2014 Dec; 66(6):1078-91. PubMed ID: 25151017
[TBL] [Abstract][Full Text] [Related]
35. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
Roggisch J; Ecke T; Koch S
Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
[TBL] [Abstract][Full Text] [Related]
36. Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis.
Ehdaie B; Theodorescu D
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1103-10. PubMed ID: 18588455
[TBL] [Abstract][Full Text] [Related]
37. MMP23B expression and protein levels in blood and urine are associated with bladder cancer.
Allione A; Pardini B; Viberti C; Giribaldi G; Turini S; Di Gaetano C; Guarrera S; Cordero F; Oderda M; Allasia M; Gontero P; Sacerdote C; Vineis P; Matullo G
Carcinogenesis; 2018 Oct; 39(10):1254-1263. PubMed ID: 30052775
[TBL] [Abstract][Full Text] [Related]
38. Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder.
Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F
Urology; 1999 Oct; 54(4):656-61. PubMed ID: 10510924
[TBL] [Abstract][Full Text] [Related]
39. B domain containing Tenascin-C: a new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder?
Gecks T; Junker K; Franz M; Richter P; Walther M; Voigt A; Neri D; Kosmehl H; Wunderlich H; Kiehntopf M; Berndt A
Clin Chim Acta; 2011 Oct; 412(21-22):1931-6. PubMed ID: 21763295
[TBL] [Abstract][Full Text] [Related]
40. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
